baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Opko Health Inc/ US68375N1037 /

2024-05-23 10:00:00 PM	Chg. -0.0400	Volume	Bid1:38:14 AM	Ask1:38:14 AM	High	Low
1.2800USD	-3.03%	2.79 mill. Turnover: 3.35 mill.	1.2700Bid Size: 4,300	1.3000Ask Size: 7,500	1.3300	1.2600

GlobeNewswire 05-15 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

GlobeNewswire 05-13 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...

GlobeNewswire 05-10 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

GlobeNewswire 05-07 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

GlobeNewswire 05-03 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire 04-08 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...

GlobeNewswire 03-26 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...

GlobeNewswire 03-20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...

GlobeNewswire 03-08 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire 03-05 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the ...

GlobeNewswire 03-04 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire 02-28 AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

GlobeNewswire 02-27 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

GlobeNewswire 02-22 OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

GlobeNewswire 02-02 SAB Biotherapeutics Announces Executive Leadership Change

GlobeNewswire 01-30 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire 01-09 OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 ...

GlobeNewswire 01-08 OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 01-05 OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

GlobeNewswire 01-03 OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

GlobeNewswire 01-03 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire 2023-12-26 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

GlobeNewswire 2023-11-29 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...

GlobeNewswire 2023-11-14 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...

GlobeNewswire 2023-11-09 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...

Opko Health Inc/ US68375N1037 /

If you wish to receive reply to your feedback, please provide your email address.